Tislelizumab is a monoclonal antibody medicine used to treat certain types of non-small cell lung cancer (NSCLC). It works by interfering with the growth of cancer cells, thus slowing the spread of cancer. The medicine is given intravenously (into a vein) once every 3 weeks. Common side effects include fatigue, nausea, and diarrhea.
Tislelizumab is a drug currently being studied and used for some cancers. Here's a breakdown of what it is and what it does:
Function: Tislelizumab is a PD-1 checkpoint inhibitor medication [1, 2].
Mechanism: PD-1 stands for programmed cell death protein 1. Normally, this protein helps regulate the immune system by preventing T cells (immune cells) from attacking healthy cells. Certain cancers can exploit this process to evade immune attack. Tislelizumab works by blocking PD-1, thereby allowing T cells to recognize and destroy cancer cells [1, 2].
Current Uses:
- Esophageal squamous cell carcinoma (ESCC): It's approved for the treatment of unresectable, locally advanced, or metastatic ESCC [2, 3].
- Hepatocellular carcinoma (HCC): Tislelizumab is approved as a single-agent treatment for adults with HCC who haven't received prior systemic therapy [2, 3].
- Additionally: It's being investigated in clinical trials for various other solid tumors and hematological malignancies (blood cancers) [2, 4].
Important Considerations:
- Tislelizumab is administered through intravenous (IV) infusion [2].
- Like many medications, it can cause side effects. Some common ones include fatigue, nausea, diarrhea, rash, and infections [2].
- Tislelizumab is still under development for some cancers, and more studies are ongoing to determine its effectiveness and optimal use [4].